Related references
Note: Only part of the references are listed.Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
Selvi Durmus et al.
MOLECULAR PHARMACEUTICS (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)
Rajendar K. Mittapalli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens
V. Chiarion-Sileni et al.
BRITISH JOURNAL OF CANCER (2011)
Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis
Toshihiro Seike et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
R. Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis
Eun Sung Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The role of the organ microenvironment in brain metastasis
Isaiah J. Fidler
SEMINARS IN CANCER BIOLOGY (2011)
Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients
Ameer L. Elaimy et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2011)
Determinants of survival in patients with brain metastases from cutaneous melanoma
M. Staudt et al.
BRITISH JOURNAL OF CANCER (2010)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide
Tobias Sinnberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
SubbaRao V. Madhunapantula et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G. Lasithiotakis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma
F Meier et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Human melanoma progression in skin reconstructs - Biological significance of bFGF
F Meier et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
